A previous study reported that abemaciclib enhances the binding of p53 to the promoter region of the target gene CDKN1A (p21), thereby promoting the occurrence of cellular senescence in mice and breast cancer patients [46]. This evidence concerns the gene CDKN1A and breast cancer.